NeuBase Therapeutics Inc O7P
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 37
Valuation
|
Metric
|
O7P
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.16 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
O7P
Financial Strength
|
Metric
|
O7P
|
|---|---|
Quick Ratio | 2.70 |
Current Ratio | 2.87 |
Interest Coverage | −2,824.19 |
Quick Ratio
O7P
Profitability
|
Metric
|
O7P
|
|---|---|
Return on Assets (Normalized) | −49.54% |
Return on Equity (Normalized) | −78.42% |
Return on Invested Capital (Normalized) | −60.13% |
Return on Assets
O7P
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ltvkpcmq | Njghl | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lfjdsbymg | Htdbxr | $114.2 Bil | |||
| Moderna Inc
MRNA
| Bjcfjthk | Zjzc | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Gytlsvzv | Grqs | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kqhmnqxx | Mphnx | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Crjjrxt | Lcrldfr | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lsqpxttw | Srmprmn | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Fyxcwgs | Wcbw | $12.8 Bil | |||
| Incyte Corp
INCY
| Ndmmrnj | Fstmhgm | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Brfdcmkv | Wvrdx | $12.2 Bil |